SL
Siren LLC Portfolio holdings
AUM
$1.93B
This Quarter Return
+73.94%
1 Year Return
+118.08%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$2.26B
AUM Growth
+$2.26B
(+13%)
Cap. Flow
+$139M
Cap. Flow
% of AUM
6.12%
Top 10 Holdings %
Top 10 Hldgs %
48.55%
Holding
132
New
22
Increased
22
Reduced
21
Closed
14
Top Buys
| 1 |
SEPN
Septerna, Inc. Common Stock
SEPN
|
$50.4M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$38.9M |
| 3 |
Apogee Therapeutics
APGE
|
$33.9M |
| 4 |
NewAmsterdam Pharma
NAMS
|
$30.2M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$25.8M |
Top Sells
| 1 |
Scholar Rock
SRRK
|
$86.8M |
| 2 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$30.1M |
| 3 |
Wave Life Sciences
WVE
|
$24.4M |
| 4 |
argenx
ARGX
|
$17.6M |
| 5 |
Biohaven
BHVN
|
$14.2M |
Sector Composition
| 1 | Healthcare | 92.88% |
| 2 | Technology | 3.51% |
| 3 | Communication Services | 1.85% |
| 4 | Consumer Discretionary | 0.74% |
| 5 | Real Estate | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Scholar Rock
SRRK
$3.14B
| $400M | 17.66% |
9,250,005
-2,009,433
| -18% | -$86.8M |
|
|
ONC
2
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $121M | 5.33% |
653,721
+90,407
| +16% | +$16.7M |
|
3
Kymera Therapeutics
KYMR
$2.95B
| $119M | 5.28% |
2,969,733
| – | – |
|
4
Apellis Pharmaceuticals
APLS
$3.48B
| $89.9M | 3.97% |
2,816,258
+649,034
| +30% | +$20.7M |
|
5
Crinetics Pharmaceuticals
CRNX
$2.92B
| $82.3M | 3.64% |
1,609,652
+300,000
| +23% | +$15.3M |
|
|
6
argenx
ARGX
$43.6B
| $70.8M | 3.13% |
115,045
-28,602
| -20% | -$17.6M |
|
|
BCAX
7
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $57M | 2.52% |
3,272,827
+200,000
| +7% | +$3.48M |
|
8
Arrowhead Research
ARWR
$3.05B
| $54.6M | 2.41% |
2,901,681
+442,903
| +18% | +$8.33M |
|
|
9
NewAmsterdam Pharma
NAMS
$2.71B
| $53.9M | 2.38% |
2,095,638
+1,175,074
| +128% | +$30.2M |
|
|
SEPN
10
Septerna, Inc. Common Stock
SEPN
$539M
| $50.4M | 2.23% |
+2,202,514
| New | +$50.4M |
|
|
CNTA
11
Centessa Pharmaceuticals
CNTA
$2.25B
| $50.3M | 2.22% |
3,004,677
-254,000
| -8% | -$4.25M |
|
|
SWTX
12
DELISTED
SpringWorks Therapeutics
SWTX
| $49.8M | 2.2% |
1,377,701
| – | – |
|
13
Neumora Therapeutics
NMRA
$280M
| $46.6M | 2.06% |
4,396,100
+1,789,529
| +69% | +$19M |
|
|
14
Wave Life Sciences
WVE
$1.53B
| $46.4M | 2.05% |
3,750,491
-1,970,681
| -34% | -$24.4M |
|
15
Ascendis Pharma
ASND
$11.8B
| $40.9M | 1.81% |
297,321
-50,600
| -15% | -$6.97M |
|
|
16
Madrigal Pharmaceuticals
MDGL
$9.76B
| $38.9M | 1.72% |
+125,942
| New | +$38.9M |
|
17
Taboola.com
TBLA
$991M
| $36.4M | 1.61% |
9,969,495
| – | – |
|
|
18
Apogee Therapeutics
APGE
$2.17B
| $33.9M | 1.5% |
+747,325
| New | +$33.9M |
|
19
Merus
MRUS
$4.98B
| $33M | 1.46% |
784,412
+102,211
| +15% | +$4.3M |
|
20
Avidity Biosciences
RNA
$5.99B
| $32.8M | 1.45% |
1,127,295
-313,441
| -22% | -$9.11M |
|
21
Vera Therapeutics
VERA
$1.38B
| $32.1M | 1.42% |
758,465
-79,463
| -9% | -$3.36M |
|
22
Dyne Therapeutics
DYN
$1.92B
| $31.7M | 1.4% |
1,347,456
+212,792
| +19% | +$5.01M |
|
23
Xenon Pharmaceuticals
XENE
$2.98B
| $29.2M | 1.29% |
743,769
| – | – |
|
24
Lexicon Pharmaceuticals
LXRX
$400M
| $28.8M | 1.27% |
38,918,903
| – | – |
|
|
BCYC
25
Bicycle Therapeutics
BCYC
$511M
| $25.8M | 1.14% |
+1,839,398
| New | +$25.8M |
|